Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mehran Karimi

Showing results (191-200 of 315) with videos related to

Pageof 32
Sort By:
Sao Paulo Medical Journal = Revista Paulista De Medicina|August 2, 2013
Quality of life among Iranian patients with beta-thalassemia major using the SF-36 questionnaireSezaneh Haghpanah, Shiva Nasirabadi, Fariborz Ghaffarpasand, et al.
Annals of Hematology|July 29, 2021
Expression of the immune checkpoint receptors CTLA-4, LAG-3, and TIM-3 in β-thalassemia major patients: correlation with alloantibody production and regulatory T cells (Tregs) phenotypeNegin Shokrgozar, Mehran Karimi, Hossein Golmoghaddam, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|March 19, 2008
Is beta-thalassemia trait a protective factor against ischemic cerebrovascular accidents?Mehran Karimi, Afshin Borhani Haghighi, Maryam Yazdani, et al.
Fundamental & Clinical Pharmacology|May 21, 2009
Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trialMarjan Gharagozloo, Behjat Moayedi, Maryam Zakerinia, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|October 21, 2015
Efficacy and safety of factor eight inhibitor bypassing activity prophylaxis evaluation in young patients with hemophilia and high titer inhibitorMehran Karimi, Hakimeh Tavoosi, Sezaneh Haghpanah, et al.
Medical Journal of the Islamic Republic of Iran|February 10, 2015
Serum cancer antigen 15.3 concentrations in patients with betathalassemia minor compared to those with cancer and healthy individualsMahdi Shahriari, Sezaneh Haghpanah, Javad Dehghani, et al.
Iranian Journal of Medical Sciences|January 24, 2014
Hypothyroidism in β-Thalassemia Intermedia Patients with and without HydroxyureaOmid Reza Zekavat, Ali Reza Makarem, Sezaneh Haghpanah, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|December 14, 2011
Arg77His and Trp187Arg are the most common mutations causing FXIII deficiency in IranPeyman Eshghi, Nader Cohan, Manigeh Lak, et al.
Acta Bio-Medica : Atenei Parmensis|July 1, 2022
The evolution of glucose-insulin homeostasis in children with β-thalassemia major (β -TM): A twenty-year retrospective ICET- A observational analysis from early childhood to young adulthoodVincenzo De Sanctis, Shahina Daar, Ashraf T Soliman, et al.
Iranian Journal of Pharmaceutical Research : IJPR|September 20, 2016
Long Term Follow up Study on a Large Group of Patients with Congenital Factor XIII Deficiency Treated Prophylactically with Fibrogammin P®Majid Naderi, Mehran Karimi, Maryam Sadat Hosseini, et al.
Pageof 32

Showing results (191-200 of 315) with videos related to

Sort By:
Pageof 32
Sao Paulo Medical Journal = Revista Paulista De Medicina|August 2, 2013
Quality of life among Iranian patients with beta-thalassemia major using the SF-36 questionnaireSezaneh Haghpanah, Shiva Nasirabadi, Fariborz Ghaffarpasand, et al.
Annals of Hematology|July 29, 2021
Expression of the immune checkpoint receptors CTLA-4, LAG-3, and TIM-3 in β-thalassemia major patients: correlation with alloantibody production and regulatory T cells (Tregs) phenotypeNegin Shokrgozar, Mehran Karimi, Hossein Golmoghaddam, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|March 19, 2008
Is beta-thalassemia trait a protective factor against ischemic cerebrovascular accidents?Mehran Karimi, Afshin Borhani Haghighi, Maryam Yazdani, et al.
Fundamental & Clinical Pharmacology|May 21, 2009
Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trialMarjan Gharagozloo, Behjat Moayedi, Maryam Zakerinia, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|October 21, 2015
Efficacy and safety of factor eight inhibitor bypassing activity prophylaxis evaluation in young patients with hemophilia and high titer inhibitorMehran Karimi, Hakimeh Tavoosi, Sezaneh Haghpanah, et al.
Medical Journal of the Islamic Republic of Iran|February 10, 2015
Serum cancer antigen 15.3 concentrations in patients with betathalassemia minor compared to those with cancer and healthy individualsMahdi Shahriari, Sezaneh Haghpanah, Javad Dehghani, et al.
Iranian Journal of Medical Sciences|January 24, 2014
Hypothyroidism in β-Thalassemia Intermedia Patients with and without HydroxyureaOmid Reza Zekavat, Ali Reza Makarem, Sezaneh Haghpanah, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|December 14, 2011
Arg77His and Trp187Arg are the most common mutations causing FXIII deficiency in IranPeyman Eshghi, Nader Cohan, Manigeh Lak, et al.
Acta Bio-Medica : Atenei Parmensis|July 1, 2022
The evolution of glucose-insulin homeostasis in children with β-thalassemia major (β -TM): A twenty-year retrospective ICET- A observational analysis from early childhood to young adulthoodVincenzo De Sanctis, Shahina Daar, Ashraf T Soliman, et al.
Iranian Journal of Pharmaceutical Research : IJPR|September 20, 2016
Long Term Follow up Study on a Large Group of Patients with Congenital Factor XIII Deficiency Treated Prophylactically with Fibrogammin P®Majid Naderi, Mehran Karimi, Maryam Sadat Hosseini, et al.
Pageof 32